Wall Street Zen downgrades Intuitive Surgical stock to Hold
π Wall Street Zen downgrades Intuitive Surgical stock from Buy to Hold due to valuation concerns despite strong fundamentals.
π° Second-quarter revenue surged 18.40 percent year over year to reach USD 2.89 billion, demonstrating continued sales momentum.
π Market capitalization is valued at USD 142.2 billion with shares trading near EUR 359.95 on October 1, 2026.
π― Analyst consensus target price sits at USD 508.68, though JPMorgan recently cut its specific target to USD 450.00.
π The next key data point is the third-quarter earnings report expected on October 20, 2026.
π₯ Intuitive Surgical operates in the Healthcare sector as a leader in medical instruments and surgical robotics.
Bullish Signals
- Intuitive Surgical achieved an 18.40 percent year-over-year revenue increase in the second quarter, generating USD 2.89 billion in sales.
- The company maintains a substantial market capitalization of USD 142.2 billion, indicating strong investor confidence in its long-term position.
- A majority of analysts (22 out of 31) still rate the stock as a Buy, suggesting broad institutional support despite the downgrade.
Risk Factors
- Wall Street Zen downgraded the stock from Buy to Hold, signaling concerns that the current valuation is stretched relative to recent highs.
- JPMorgan cut its price target from USD 550.00 to USD 450.00 in July, reflecting a more bearish view on near-term upside potential.
- The stock remains below its one-year high of USD 603.88, indicating that the market has not yet fully priced in the recent growth.
Full Analysis
Wall Street Zen has downgraded Intuitive Surgical (ISRG) stock from a Buy rating to a Hold, citing a wide valuation range despite the company's expanding operating picture. This analyst sentiment shift reflects market caution regarding the stock price relative to its one-year highs, even as broader consensus remains broadly constructive with 22 analysts maintaining Buy ratings against eight Holds and one Sell.
Intuitive Surgical reported robust second-quarter revenue growth of 18.40 percent year over year, generating USD 2.89 billion in sales. This strong momentum serves as a counterweight to the more cautious analyst downgrades, suggesting that while the stock valuation is being reassessed, the underlying business fundamentals and sales velocity remain measurable and positive.
The company's market capitalization stands at USD 142.2 billion as of October 1, 2026, with shares trading around EUR 359.95 on European exchanges. Investors are now focused on the upcoming third-quarter earnings report scheduled for October 20, 2026, which will serve as a critical checkpoint to determine if the second-quarter growth rate can be sustained.